NASDAQ
On June 15, 2026, we delve into the DCF analysis for Amgen Inc (AMGN), a company that has shown strong price performance over the past year, with a 23.1% increa...
The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody discovery platform Delaw...
Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine. Drugmakers pitched doctors and investors on their future drugs at the recent Am...
Amgen said it has signed up a research firm to independently review data for its drug, Tavneos, as it seeks to prove its benefits following the U.S. health regulator's proposal to withdraw it from t...
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect...
In the closing of the recent trading day, Amgen (AMGN) stood at $337.5, denoting a -2.05% move from the preceding trading day....
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend....
MariTide's less frequent dosing could help AMGN carve out a place in the rapidly expanding obesity drug market....
Amgen Inc. (AMGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript...
Amgen NASDAQ: AMGN executives said the company's first-quarter performance supports its view that 2026 can serve as a “springboard year,” with growth products helping offset increased competition for ...
No price data available for this timeframe.